Roche shares drop as oral breast cancer drug fails in trial

Company Overview - Roche shares fell over 5% following the failure of its drug candidate giredestrant in a phase III trial for treating newly diagnosed breast cancer patients [1] - The stock reached its lowest point in about a month, down 5.1% at 0846 GMT [1] Trial Results - The phase III trial did not provide reliable evidence that giredestrant, when used in combination with Pfizer's Ibrance, slows disease progression compared to standard hormonal therapy plus Ibrance [1] - This outcome represents a significant reversal for the giredestrant pill, which previously showed promise by reducing the risk of tumor recurrence in breast cancer patients who had received established initial treatment [1] Market Context - Giredestrant is classified as an oral selective estrogen receptor degrader (SERD), targeting tumors that grow in response to estrogen, which accounts for up to 80% of breast cancer cases [1] - The market potential for this drug class has attracted competitors, including AstraZeneca, which is developing a rival compound, camizestrant [1]